Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib DDI Study with Itraconazole or Rifampicin in Healthy Participants
NCT07768111Phase 1Not yet recruiting
- Sponsor
- Zenitar
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of flonoltinib in rheumatoid arthritis (RA) (2 arms), sponsored by Zenitar. Primary endpoints: Maximum Observed Plasma Concentration at 144 hours, Time to Maximum Plasma Concentration at 144 hours and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
flonoltinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07768111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768111.